$MRK Headlines Why the M&A outbreak hurts Big
Post# of 44860
Posted On: 02/08/2015 10:54:36 AM
$MRK Headlines
Why the M&A outbreak hurts Big Pharma 10:30 a.m. Feb. 5, 2015 - David Weidner
Keurig Green Mountain burned by weak outlook, sales 6:35 p.m. Feb. 4, 2015 - Sue Chang
U.S. stocks end lower as ECB reject Greek bonds as collateral 4:33 p.m. Feb. 4, 2015 - Barbara Kollmeyer
Gilead to discount its pricey Sovaldi drug 1:55 p.m. Feb. 4, 2015 - Russ Britt
Careful what you wish for: Oil-price recovery may sting 8:28 a.m. Feb. 4, 2015 - Shawn Langlois
Merck sales fall amid headwinds 7:24 a.m. Feb. 4, 2015 - MarketWatch.com
Merck's stock falls 1.7% after earnings 7:16 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck sees 2015 sales of $38.3 bln to $39.8 bln 7:15 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck expects 2015 EPS $1.62-$1.91, adj. EPS of $3.32-$3.47 7:13 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck Q4 revenue falls 7% to $10.48 bln from $11.32 bln 7:12 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck reports Q4 EPS of $2.54, adj. EPS of $0.87 7:11 a.m. Feb. 4, 2015 - Silvia Ascarelli
What to look for in Merck earnings 11:41 a.m. Feb. 2, 2015 - Peter Loftus
Gasoline ‘tax cut’ in focus on energy, consumer-based earnings 6:13 a.m. Feb. 2, 2015 - Wallace Witkowski
Does Jersey’s lagging economy doom Christie’s bid? 8:31 a.m. Jan. 26, 2015 - Tim Mullaney
How you can cash in on the dollar’s coming decline 6:01 a.m. Jan. 22, 2015 - Michael Brush
Don’t look for pricey hepatitis drugs to come down 2:32 p.m. Jan. 13, 2015 - Russ Britt
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Bristol-Myers Squibb jumps on Opdivo cancer drug test 8:17 a.m. Jan. 12, 2015 - Angela Chen
Here are the best-performing stocks so far in 2015 11:47 a.m. Jan. 9, 2015 - Philip van Doorn
Ebola vaccines ready for West Africa tests: WHO 11:11 a.m. Jan. 9, 2015 - MarketWatch.com
In Perspective: The Ridiculously Large Market Caps Of America's 20 Most Valuable Companies 21 min ago - Seeking Alpha
Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics 4:46 a.m. Today - Seeking Alpha
AbbVie: Big Pharma at a Discount Price 4:24 a.m. Feb. 7, 2015 - Barrons.com
Gilead’s Dividend Debut; GM Relents 9:38 p.m. Feb. 6, 2015 - Barrons.com
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More 4:00 p.m. Feb. 6, 2015 - Seeking Alpha
Dow 30 Stock Roundup: Disney, Exxon Beat, United Technologies Raises Dividend - Analyst Blog 2:15 p.m. Feb. 6, 2015 - Zacks.com
Gabelli's Q4 Picks Include Acquisition Targets 9:44 a.m. Feb. 6, 2015 - GuruFocus.com
Merck prices debt offering 7:04 a.m. Feb. 6, 2015 - Seeking Alpha
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx 6:05 a.m. Feb. 6, 2015 - TheStreet.com
U.S. Stocks Post Big Rebound This Week, Still Best Investment 3:56 p.m. Feb. 5, 2015 - TheStreet.com
Dow Jones (DJIA) Today: Merck (MRK) Lower 2:00 p.m. Feb. 5, 2015 - TheStreet.com
Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary 11:00 a.m. Feb. 5, 2015 - Zacks.com
Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 10:35 a.m. Feb. 5, 2015 - GuruFocus.com
The Reasons That Make Pfizer A Worthy Hold. 10:19 a.m. Feb. 5, 2015 - GuruFocus.com
Company News for February 05, 2015 - Corporate Summary 10:10 a.m. Feb. 5, 2015 - Zacks.com
Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines 9:31 a.m. Feb. 5, 2015 - 247WallSt.com
Mixed Signals, Extreme Volatility Plague Market 8:04 p.m. Feb. 4, 2015 - InvestorPlace.com
Stocks Falter After ECB Move 4:52 p.m. Feb. 4, 2015 - The Wall Street Journal Interactive Edition
Merck Sales Fall on Stronger Dollar, Patent Expirations 2:21 p.m. Feb. 4, 2015 - The Wall Street Journal Interactive Edition
HCV Stocks Struggle As Gilead, Merck Face Headwinds 11:12 a.m. Feb. 4, 2015 - Investors Business Daily
Fitch Rates Merck's Debt Offering 'A+'; Outlook Negative 1:07 p.m. Feb. 6, 2015 - BusinessWire - BZX
Merck Prices $8.0 Billion Debt Offering 7:37 p.m. Feb. 5, 2015 - BusinessWire - BZX
World Membrane Separation Technologies Industry, Global Industry Analysts 2:28 p.m. Feb. 5, 2015 - PR Newswire - PRF
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany 2:32 p.m. Feb. 3, 2015 - PR Newswire - PRF
Merck’s Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 8:00 a.m. Feb. 3, 2015 - BusinessWire - BZX
Merck's Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 8:00 a.m. Feb. 3, 2015 - PR Newswire - PRF
Technical Commentary on Pharma Stocks -- Merck, AbbVie, Bristol-Myers Squibb, Shire, and Mallinckrodt 8:45 a.m. Jan. 30, 2015 - PR Newswire - PRF
Hortonworks Establishes Data Governance Initiative 9:00 a.m. Jan. 28, 2015 - PR Newswire - PRF
Global Pediatric Drugs and Vaccines Market 11:56 a.m. Jan. 27, 2015 - PR Newswire - PRF
TransCelerate BioPharma Welcomes Merck & Co. and Novo Nordisk to its Membership Roster 11:25 a.m. Jan. 27, 2015 - BusinessWire - BZX
TransCelerate BioPharma Welcomes Merck & Co. and Novo Nordisk to its Membership Roster 10:00 a.m. Jan. 27, 2015 - BusinessWire - BZX
Euclises Announces Appointment of Bobby Sandage as New CEO 8:00 a.m. Jan. 27, 2015 - BusinessWire - BZX
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 12:33 p.m. Jan. 26, 2015 - PR Newswire - PRF
Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO® (tedizolid phosphate) 8:30 a.m. Jan. 26, 2015 - BusinessWire - BZX
Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist’s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 3:29 p.m. Jan. 22, 2015 - BusinessWire - BZX
Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors 8:01 a.m. Jan. 22, 2015 - BusinessWire - BZX
Merck Completes Tender Offer to Acquire Cubist 8:03 a.m. Jan. 21, 2015 - BusinessWire - BZX
Dana Holding Set to Join the S&P MidCap 400 5:45 p.m. Jan. 20, 2015 - PR Newswire - PRF
Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024 10:36 a.m. Jan. 15, 2015 - PR Newswire - PRF
Insider Trading Alerts for Google, Oasis Petroleum, Best Buy, Twitter, Merck, and First Niagara Financial Group 8:45 a.m. Jan. 15, 2015 - PR Newswire - PRF
Why the M&A outbreak hurts Big Pharma 10:30 a.m. Feb. 5, 2015 - David Weidner
Keurig Green Mountain burned by weak outlook, sales 6:35 p.m. Feb. 4, 2015 - Sue Chang
U.S. stocks end lower as ECB reject Greek bonds as collateral 4:33 p.m. Feb. 4, 2015 - Barbara Kollmeyer
Gilead to discount its pricey Sovaldi drug 1:55 p.m. Feb. 4, 2015 - Russ Britt
Careful what you wish for: Oil-price recovery may sting 8:28 a.m. Feb. 4, 2015 - Shawn Langlois
Merck sales fall amid headwinds 7:24 a.m. Feb. 4, 2015 - MarketWatch.com
Merck's stock falls 1.7% after earnings 7:16 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck sees 2015 sales of $38.3 bln to $39.8 bln 7:15 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck expects 2015 EPS $1.62-$1.91, adj. EPS of $3.32-$3.47 7:13 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck Q4 revenue falls 7% to $10.48 bln from $11.32 bln 7:12 a.m. Feb. 4, 2015 - Silvia Ascarelli
Merck reports Q4 EPS of $2.54, adj. EPS of $0.87 7:11 a.m. Feb. 4, 2015 - Silvia Ascarelli
What to look for in Merck earnings 11:41 a.m. Feb. 2, 2015 - Peter Loftus
Gasoline ‘tax cut’ in focus on energy, consumer-based earnings 6:13 a.m. Feb. 2, 2015 - Wallace Witkowski
Does Jersey’s lagging economy doom Christie’s bid? 8:31 a.m. Jan. 26, 2015 - Tim Mullaney
How you can cash in on the dollar’s coming decline 6:01 a.m. Jan. 22, 2015 - Michael Brush
Don’t look for pricey hepatitis drugs to come down 2:32 p.m. Jan. 13, 2015 - Russ Britt
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Bristol-Myers Squibb jumps on Opdivo cancer drug test 8:17 a.m. Jan. 12, 2015 - Angela Chen
Here are the best-performing stocks so far in 2015 11:47 a.m. Jan. 9, 2015 - Philip van Doorn
Ebola vaccines ready for West Africa tests: WHO 11:11 a.m. Jan. 9, 2015 - MarketWatch.com
In Perspective: The Ridiculously Large Market Caps Of America's 20 Most Valuable Companies 21 min ago - Seeking Alpha
Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics 4:46 a.m. Today - Seeking Alpha
AbbVie: Big Pharma at a Discount Price 4:24 a.m. Feb. 7, 2015 - Barrons.com
Gilead’s Dividend Debut; GM Relents 9:38 p.m. Feb. 6, 2015 - Barrons.com
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More 4:00 p.m. Feb. 6, 2015 - Seeking Alpha
Dow 30 Stock Roundup: Disney, Exxon Beat, United Technologies Raises Dividend - Analyst Blog 2:15 p.m. Feb. 6, 2015 - Zacks.com
Gabelli's Q4 Picks Include Acquisition Targets 9:44 a.m. Feb. 6, 2015 - GuruFocus.com
Merck prices debt offering 7:04 a.m. Feb. 6, 2015 - Seeking Alpha
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx 6:05 a.m. Feb. 6, 2015 - TheStreet.com
U.S. Stocks Post Big Rebound This Week, Still Best Investment 3:56 p.m. Feb. 5, 2015 - TheStreet.com
Dow Jones (DJIA) Today: Merck (MRK) Lower 2:00 p.m. Feb. 5, 2015 - TheStreet.com
Big Pharma Weak Guidance Put These ETFs in Focus - ETF News And Commentary 11:00 a.m. Feb. 5, 2015 - Zacks.com
Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 10:35 a.m. Feb. 5, 2015 - GuruFocus.com
The Reasons That Make Pfizer A Worthy Hold. 10:19 a.m. Feb. 5, 2015 - GuruFocus.com
Company News for February 05, 2015 - Corporate Summary 10:10 a.m. Feb. 5, 2015 - Zacks.com
Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines 9:31 a.m. Feb. 5, 2015 - 247WallSt.com
Mixed Signals, Extreme Volatility Plague Market 8:04 p.m. Feb. 4, 2015 - InvestorPlace.com
Stocks Falter After ECB Move 4:52 p.m. Feb. 4, 2015 - The Wall Street Journal Interactive Edition
Merck Sales Fall on Stronger Dollar, Patent Expirations 2:21 p.m. Feb. 4, 2015 - The Wall Street Journal Interactive Edition
HCV Stocks Struggle As Gilead, Merck Face Headwinds 11:12 a.m. Feb. 4, 2015 - Investors Business Daily
Fitch Rates Merck's Debt Offering 'A+'; Outlook Negative 1:07 p.m. Feb. 6, 2015 - BusinessWire - BZX
Merck Prices $8.0 Billion Debt Offering 7:37 p.m. Feb. 5, 2015 - BusinessWire - BZX
World Membrane Separation Technologies Industry, Global Industry Analysts 2:28 p.m. Feb. 5, 2015 - PR Newswire - PRF
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany 2:32 p.m. Feb. 3, 2015 - PR Newswire - PRF
Merck’s Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 8:00 a.m. Feb. 3, 2015 - BusinessWire - BZX
Merck's Insomnia Medicine BELSOMRA® (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 8:00 a.m. Feb. 3, 2015 - PR Newswire - PRF
Technical Commentary on Pharma Stocks -- Merck, AbbVie, Bristol-Myers Squibb, Shire, and Mallinckrodt 8:45 a.m. Jan. 30, 2015 - PR Newswire - PRF
Hortonworks Establishes Data Governance Initiative 9:00 a.m. Jan. 28, 2015 - PR Newswire - PRF
Global Pediatric Drugs and Vaccines Market 11:56 a.m. Jan. 27, 2015 - PR Newswire - PRF
TransCelerate BioPharma Welcomes Merck & Co. and Novo Nordisk to its Membership Roster 11:25 a.m. Jan. 27, 2015 - BusinessWire - BZX
TransCelerate BioPharma Welcomes Merck & Co. and Novo Nordisk to its Membership Roster 10:00 a.m. Jan. 27, 2015 - BusinessWire - BZX
Euclises Announces Appointment of Bobby Sandage as New CEO 8:00 a.m. Jan. 27, 2015 - BusinessWire - BZX
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 12:33 p.m. Jan. 26, 2015 - PR Newswire - PRF
Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO® (tedizolid phosphate) 8:30 a.m. Jan. 26, 2015 - BusinessWire - BZX
Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist’s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior Notes due 2020 3:29 p.m. Jan. 22, 2015 - BusinessWire - BZX
Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors 8:01 a.m. Jan. 22, 2015 - BusinessWire - BZX
Merck Completes Tender Offer to Acquire Cubist 8:03 a.m. Jan. 21, 2015 - BusinessWire - BZX
Dana Holding Set to Join the S&P MidCap 400 5:45 p.m. Jan. 20, 2015 - PR Newswire - PRF
Vaccine Manufacturing Technology and Services: World Market Forecast 2014-2024 10:36 a.m. Jan. 15, 2015 - PR Newswire - PRF
Insider Trading Alerts for Google, Oasis Petroleum, Best Buy, Twitter, Merck, and First Niagara Financial Group 8:45 a.m. Jan. 15, 2015 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼